Roche, as a world leader in diagnostics and drug development, is in the fortunate situation of having more candidates in its portfolio than its resources can handle. Its solution is its partnering culture. In January 2007, Roche signed a licensing agreement with newly created Synosia Therapeutics, giving Synosia five CNS compounds. This article, based on an interview between Fintan Walton of PharmaVentures and Tom Woiwode of Synosia, examines Synosia#8217;s unusual origins (within a venture capitalist firm), the significance of its Roche-friendly management team, the maintenance of the deal with Roche, and the future of Synosia and its compounds.